Carrie B. Lee, MD, MPH
Dr. Carrie Lee is a medical and thoracic oncologist at the University of North Carolina at Chapel Hill and a Professor at the UNC School of Medicine. Her clinical practice focuses on lung cancer, and she has experience with traditional chemotherapy protocols as well as novel regimens. She is also the Chief Medical Officer for UNC Lineberger Comprehensive Cancer Center’s Clinical Research.
Education and Career
Dr. Lee earned her medical degree at Northeast Ohio Medical University. After graduation, she completed her internship and Residency in Internal Medicine at the University of North Carolina Hospitals and never left.
Following completion of her residency, she completed a fellowship in Hematology and Medical Oncology as well as a residency in Public Health and General Preventive Medicine.[1]
Today, Dr. Lee is a professor in the Division of Hematology/Oncology and Chief Medical Officer of UNC Lineberger Clinical Research. She is also the Medical Director of the N.C. Basnight Cancer Hospital Clinical Trial Unit.
Dr. Lee’s clinical practice focuses on lung cancer treatment. While her focus is on lung cancers, she also treats mesothelioma and melanoma.
Dr. Lee loves taking care of people. She has a passion for providing compassionate oncology care and says that when she treats patients, she approaches them as a whole person rather than as a statistic. She approaches each with attention to how the illness is impacting their day-to-day life as well as how it affects the other people in their lives.[1]
Dr. Lee has been appointed chair of the Association of American Cancer Institute’s Clinical Research Initiative Steering Committee, which is responsible for developing better methods to disseminate information across cancer centers, identifying and addressing clinical research challenges, and measuring progress on behalf of AACI. She is also a member of the American Society of Clinical Oncology.[2]
Research
Dr. Lee is passionate about advancing the science behind the development of new anti-cancer treatments. She has spent much of her career developing and leading cancer clinical trials.
The research that Dr. Lee has conducted centers on the care and outcomes of patients diagnosed with thoracic malignancies. Recent articles that she has authored or co-authored and that have been published in medical journals include:
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomized, phase 2 trial.Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13.PMID: 35033226
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.PMID: 25971938
Historical review of melanoma treatment and outcomes.
Clin Dermatol. 2013 Mar-Apr;31(2):141-7. doi: 10.1016/j.clindermatol.2012.08.015.PMID: 23438377 Review.
J Clin Oncol. 2016 Nov 1;34(31):3796-3802. doi: 10.1200/JCO.2016.69.6781.PMID: 27601549 No abstract available.
Current and evolving treatment options for limited-stage small cell lung cancer.
Curr Opin Oncol. 2006 Mar;18(2):162-72. doi: 10.1097/01.cco.0000208790.45312.25.PMID: 16462186 Review.
Clin Lung Cancer. 2006 May;7 Suppl 4:S111-7. doi: 10.3816/clc.2006.s.002.PMID: 16764751 Review.
Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA.Clin Lung Cancer. 2006 Nov;8(3):195-202. doi: 10.3816/CLC.2006.n.047.PMID: 17239295 Review.
